Back to Search
Start Over
Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts.
- Source :
- American Journal of Physiology: Heart & Circulatory Physiology; May2008, Vol. 294 Issue 5, pH2406-H2409, 4p, 1 Color Photograph, 1 Diagram, 1 Chart, 6 Graphs
- Publication Year :
- 2008
-
Abstract
- Statins have been shown to be cardioprotective; however, their interaction with endogenous cardioprotection by ischemic preconditioning and post-conditioning is not known. In the present study, we examined if acute and chronic administration of the 3-hydroxy-3-methylglutaryl CoA reductase inhibitor lovastatin affected the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Wistar rats were randomly assigned to the following three groups: 1) vehicle (1% methylcellulose per os for 12 days), 2) chronic lovastatin (15 mg·kg<superscript>-1</superscript>·day<superscript>-1</superscript> per os for 12 days), and 3) acute lovastatin (1% methylcellulose per os for 12 days and 50 µmol/l lovastatin in the perfusate). Hearts isolated from the three groups were either subjected to a nonconditioning (aerobic perfusion followed by 30-mm coronary occlusion and 120-mm reperfusion, i.e., test ischemia-reperfusion), preconditioning (three intermittent periods of 5-mm ischemia-reperfusion cycles before test ischemia-reperfusion), or postconditioning (six cycles of 10-s ischemia-reperfusion after test ischemia) perfusion protocol. Preconditioning and postconditioning significantly decreased infarct size in vehicle-treated hearts. However, preconditioning failed to decrease infarct size in acute lovastatin-treated hearts, but the effect of postconditioning remained unchanged. Chronic lovastatin treatment abolished postconditioning but not preconditioning; however, it decreased infarct size in the nonconditioned group. Myocardial levels of coenzyme Q9 were decreased in both acute and chronic lovastatin-treated rats. Western blot analysis revealed that both acute and chronic lovastatin treatment attenuated the phoshorylation of Akt; however, acute but not chronic lovastatin treatment increased the phosphorylation of p42 MAPKIERK. We conclude that, although lovastatin may lead to cardioprotection, it interferes with the mechanisms of cardiac adaptation to ischemic stress. [ABSTRACT FROM AUTHOR]
- Subjects :
- STATINS (Cardiovascular agents)
RATS
ISCHEMIA
HEART
CARDIOTONIC agents
Subjects
Details
- Language :
- English
- ISSN :
- 03636135
- Volume :
- 294
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- American Journal of Physiology: Heart & Circulatory Physiology
- Publication Type :
- Academic Journal
- Accession number :
- 32079287
- Full Text :
- https://doi.org/10.1152/ajpheart.00862.2007